Mangrove Partners’s Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 WRAC.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-75,117
Closed -$757K 407
2022
Q3
$757K Buy
+75,117
New +$6.66K 0.04% 277
2022
Q2
Sell
-200,000
Closed -$1.99M 612
2022
Q1
$1.99M Hold
200,000
0.11% 288
2021
Q4
$1.97M Buy
+200,000
New +$107K 0.12% 316

Other funds holding WRAC.WS

Mangrove Partners's WRAC.WS Position: Q4 2022 in Review

Mangrove Partners sold out of Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 (WRAC.WS) in Q4 2022, closing a stake of 75,117 shares — an estimated $757K sold.

Mangrove Partners first reported a position in WRAC.WS in Q4 2021 and held it in 3 quarters. The position peaked at $1.99M in Q1 2022. 37 funds tracked by Wall St. Rank hold WRAC.WS as of Q4 2022.

  • Mangrove Partners reported no remaining Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 position as of Q4 2022 after selling out during the quarter.
  • Mangrove Partners sold 75,117 Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 shares in Q4 2022, an estimated $757K.
  • Mangrove Partners first reported a position in Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 in Q4 2021 and held it in 3 quarters.
  • Mangrove Partners's Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 position peaked at $1.99M in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Williams Rowland Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 as of Q4 2022.

Based on Mangrove Partners's 13F filing for Q4 2022, filed 14 Feb 2023.